FILTER CONTENT
Research
By Simon EricksonPublished On: August 26, 2024Here are 3 Key Risks at TransMedics. But the Stock is Still a Buy.
By Anirban MahantiPublished On: February 15, 2024Twilio Delivers Lukewarm Results And Announces Strategic Review
By Simon EricksonPublished On: December 18, 20237investing’s 2023 Year in Review: An Updated Look at All of Our Stock Picks
